COVID-19 ‘cocktail’ therapy moves to clinical trial
Jun 26, 2020
A therapeutic, two-antibody COVID-19 treatment “cocktail” from Regeneron and the Biomedical Advanced Research and Development Authority moved to its first clinical trial, the developers earlier this month announced.
The REGN-COV2 treatment contains two neutralizing monoclonal antibodies. It is believed to have the potential to be one of the first therapeutics specifically designed to inhibit SARS-COV-2.
Novel Coronavirus (COVID-19)
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by HFACULTY News. Publisher: News Feed Click this link to read the full content from the Publisher Read More